Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CAMBRIDGE - Sage Therapeutics, Inc. announced today topline results from PRECEDENT, a double-blind, placebo-controlled Phase 2 study of the investigational oral medicine dalzanemdor in people with.
CAMBRIDGE, Mass. -March 26, 2024 Sage Therapeutics, Inc. today announced that Steve Paul, M.D. will retire from the Company s Board of Directors at the end of his current term. Dr. Paul.
Despite missing out on an FDA approval for major depressive disorder, Zurzuvae appears to be a strong asset for Sage Therapeutics, with high growth potential in 2024.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call Transcript February 14, 2024 Sage Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. Welcome to SAGE Therapeutics’ Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator […]